ATE525083T1 - Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung - Google Patents

Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Info

Publication number: ATE525083T1
Authority: AT; Austria
Prior art keywords: pharmaceutical composition; asp; insulin; analog; active compound
Prior art date: 2003-11-13

Application number

AT04797450T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Kristian Tage Hansen

Dorthe Kot Engelund

Svend Ludvigsen

Lars Hansen

Claude Bonde

Ejvind Jensen

Tine Elisabeth Gottschalk Boving

Morten Schlein

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-13

Filing date

2004-11-12

Publication date

2011-10-15

2004-11-12 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE525083T1 publication Critical patent/ATE525083T1/de

Links

108090001061 Insulin Proteins 0.000 title abstract 2
230000002473 insulinotropic effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000004094 surface-active agent Substances 0.000 title 1
235000012054 meals Nutrition 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04797450T 2003-11-13 2004-11-12 Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung ATE525083T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200301689		2003-11-13
PCT/DK2004/000788 WO2005046716A1 (en)	2003-11-13	2004-11-12	Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia

Publications (1)

Publication Number	Publication Date
ATE525083T1 true ATE525083T1 (de)	2011-10-15

Family

ID=34585770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04797450T ATE525083T1 (de)	2003-11-13	2004-11-12	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Country Status (5)

Country	Link
EP (1)	EP1684793B1 (de)
JP (1)	JP4800959B2 (de)
AT (1)	ATE525083T1 (de)
ES (1)	ES2373660T3 (de)
WO (1)	WO2005046716A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
EP3572106A1 (de)	2003-04-23	2019-11-27	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
KR101308912B1 (ko)	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
EP1633391B1 (de)	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilisierte pharmazeutische peptid zusammensetzungen
EP1687019B1 (de)	2003-11-20	2017-11-22	Novo Nordisk A/S	Für die herstellung und verwendung in injektionsvorrichtungen optimale propylenglykol enhaltende peptidformulierungen
EP2298337B1 (de)	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
WO2006014425A1 (en)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
PL1789434T3 (pl)	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
WO2006051103A2 (en) *	2004-11-12	2006-05-18	Novo Nordisk A/S	Stable formulations of peptides
EP2494983B1 (de) *	2004-11-12	2019-04-24	Novo Nordisk A/S	Stabile formulierung von glp-1
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
WO2008023050A1 (en)	2006-08-25	2008-02-28	Novo Nordisk A/S	Acylated exendin-4 compounds
JP5241849B2 (ja)	2007-11-16	2013-07-17	ノボ・ノルデイスク・エー／エス	インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
CA2711749A1 (en)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr) *	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
SG10201403840VA (en)	2009-07-06	2014-10-30	Sanofi Aventis Deutschland	Aqueous insulin preparations containing methionine
SI2498802T1 (sl)	2009-11-13	2015-05-29	Sanofi-Aventis Deutschland Gmbh	Farmacevtski sestavek, ki vsebuje agonist GLP-1, inzulin in metionin
PL2498801T3 (pl)	2009-11-13	2018-08-31	Sanofi Aventis Deutschland	Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
AU2011206629B2 (en) *	2010-01-12	2014-07-17	Novo Nordisk A/S	Pharmaceutical compositions for oral administration of insulin peptides
BR112013004756B1 (pt)	2010-08-30	2020-04-28	Sanofi Aventis Deutschland	uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2846413C (en)	2011-08-29	2021-11-02	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR092862A1 (es) *	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt)	2012-12-21	2018-02-12	Sanofi	Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
EP3091965A1 (de)	2014-01-09	2016-11-16	Sanofi	Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten
RU2016132340A (ru)	2014-01-09	2018-02-14	Санофи	Стабилизированные фармацевтические составы на основе инсулина аспарта
CA2932877A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TW201630622A (zh) *	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
CA3082033A1 (en)	2017-08-24	2019-02-28	Novo Nordisk A\S	Glp-1 compositions and uses thereof
CN113966225A (zh)	2019-06-14	2022-01-21	西兰制药公司	双重glp1/2激动剂的药物肠胃外组合物
US11318191B2 (en)	2020-02-18	2022-05-03	Novo Nordisk A/S	GLP-1 compositions and uses thereof
CN116710114B9 (zh) *	2020-12-16	2026-01-02	西兰制药公司	Glp-1/glp-2双重激动剂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
HU227021B1 (en) *	1996-08-30	2010-05-28	Novo Nordisk As	Glp-1 derivatives
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
WO1998008872A1 (en) *	1996-08-30	1998-03-05	Novo Nordisk A/S	Glp-2 derivatives
DK1629849T4 (en) *	1997-01-07	2017-12-04	Amylin Pharmaceuticals Llc	Pharmaceutical compositions comprising exedins and agonists thereof
JP2003503356A (ja) *	1999-06-25	2003-01-28	メドトロニックミニメドインコーポレイテッド	多剤糖尿病治療
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
EP1250126A2 (de) *	2000-01-11	2002-10-23	Novo Nordisk A/S	Transepitheliale verabreichung von derivaten von glp-1
WO2003020201A2 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin

2004
- 2004-11-12 JP JP2006538658A patent/JP4800959B2/ja not_active Expired - Fee Related
- 2004-11-12 ES ES04797450T patent/ES2373660T3/es not_active Expired - Lifetime
- 2004-11-12 EP EP04797450A patent/EP1684793B1/de not_active Expired - Lifetime
- 2004-11-12 WO PCT/DK2004/000788 patent/WO2005046716A1/en not_active Ceased
- 2004-11-12 AT AT04797450T patent/ATE525083T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP4800959B2 (ja)	2011-10-26
WO2005046716A1 (en)	2005-05-26
JP2007510675A (ja)	2007-04-26
EP1684793B1 (de)	2011-09-21
ES2373660T3 (es)	2012-02-07
EP1684793A1 (de)	2006-08-02

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE525083T1 (de)	2011-10-15	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
WO2006051103A3 (en)	2006-11-16	Stable formulations of peptides
ATE460942T1 (de)	2010-04-15	Exendine zur glucagon suppression
WO2005021022A3 (en)	2005-06-30	Stable formulations of peptides
ZA200606153B (en)	2007-12-27	Intranasal administration of glucose-regulating peptides
WO2006051110A3 (en)	2006-11-02	Stable formulations of insulinoptropic peptides
ATE412387T1 (de)	2008-11-15	Medizinische vorrichtungen
TNSN03116A1 (en)	2005-12-23	Pulmonary administration of chemically modified insulin
DK1180121T3 (da)	2004-03-01	Langtidsvirkende insulinotrope peptider
ATE541582T1 (de)	2012-02-15	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
AU2003234529A8 (en)	2003-12-12	Glp-1 gene delivery for the treatment of type 2 diabetes
EP2233156A3 (de)	2010-10-13	Verwendung von Aprotinin-Polypeptiden als Träger in pharmazeutischen Konjugaten
MX2023014771A (es)	2024-03-19	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CY1113755T1 (el)	2016-07-27	Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
WO2004050115A3 (en)	2004-07-22	Combination treatment using exendin-4 and thiazolidinediones
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
AU2003220956A1 (en)	2003-10-20	Insulin administration apparatus
ZA200208761B (en)	2002-11-29	Pharmaceutical form of administration for peptides, methods for its production and use.
EA200702116A1 (ru)	2008-02-28	Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
Youn et al.	2008	Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
CA3251240A1 (en)	2023-08-10	DUAL GLP-1 AND GLUCAGON AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY
WO2002011724A3 (en)	2002-08-15	Neuroprotective 2-pyridinamine compositions and related methods
EP1110568A3 (de)	2002-11-27	Medikamenteninfusionsspritze
AR016768A1 (es)	2001-08-01	COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR008025A1 (es)	1999-12-09	Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina